Mathilde Beaufils, Lauriane Travard, John Rendu and Isabelle Marty* Pages 15 - 25 ( 11 )
RyR1-related myopathies are a family of genetic neuromuscular diseases due to mutations in the RYR1 gene. No treatment exists for any of these myopathies today, which could change in the coming years with the growing number of studies dedicated to the pre-clinical assessment of various approaches, from pharmacological to gene therapy strategies, using the numerous models developed up to now. In addition, the first clinical trials for these rare diseases have just been completed or are being launched. We review the most recent results obtained for the treatment of RyR1-related myopathies, and, in view of the progress in therapeutic development for other myopathies, we discuss the possible future therapeutic perspectives for RyR1-related myopathies.
Ryanodine receptor, myopathy, pharmacological therapy, gene therapy, calcium, skeletal muscle, excitation-contraction coupling
Grenoble Institute Neurosciences, University Grenoble Alpes, INSERM, U1216, CHU Grenoble Alpes, Grenoble, Grenoble Institute Neurosciences, University Grenoble Alpes, INSERM, U1216, CHU Grenoble Alpes, Grenoble, Grenoble Institute Neurosciences, University Grenoble Alpes, INSERM, U1216, CHU Grenoble Alpes, Grenoble, Grenoble Institute Neurosciences, University Grenoble Alpes, INSERM, U1216, CHU Grenoble Alpes, Grenoble